.png){kind=logo}
Paige (Paige.AI) is an AI-powered digital pathology company transforming cancer diagnosis and treatment. Using deep learning models like Virchow and PRISM, Paige provides FDA-cleared diagnostic tools that boost accuracy, streamline workflows, and empower clinicians. By advancing research and enabling personalized cancer care, Paige is redefining pathology and improving patient outcomes worldwide.
Paige AI powered by innovation merges the modern-day artificial intelligence with digital pathology to bring about the highest precision and fastest decision-making in cancer care. The power of the technology lies in the hands of the healthcare professionals who will be able to obtain a more profound insight leading to a more confident diagnosis.
The company is devoted to providing medical research and patient outcomes with the help of data-driven advancements in technology that will not only redefine but set the new global standards in precision oncology and digital transformation.
Paige AI offers Paige Diagnostic AI, Paige Alba™, and AI Technology & Services, designed to transform cancer diagnostics and precision oncology. Its clinical-grade AI tools assist pathologists in cancer detection, molecular profiling, and research acceleration, empowering healthcare professionals with deeper, data-driven insights for informed patient care.
The main revenue sources of Paige AI include granting licenses and offering subscriptions of its AI pathology solutions, collaborations with drug manufacturers and biotechnology companies for research and development, AI solutions made to order, giving advice, and tech platform partnerships such as with Microsoft.
Client Segments: Healthcare institutions, pathology laboratories, and research organizations adopting AI to enhance diagnostic accuracy and operational efficiency.
Target Companies: Hospitals, academic medical centers, and life sciences companies focused on advancing cancer diagnostics and precision oncology.
Target Geography: Global presence with strong operations in North America, expanding partnerships across Europe, and emerging activities in Asia-Pacific.
